Bausch + Lomb Corp. (BLCO)

$15.82

+0.37

(+2.39%)▲

Market is closed - opens 8 PM, 05 Dec 2023

Insights on Bausch + Lomb Corp.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 1.03B → 1.00B (in $), with an average decrease of 2.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -32.0M → -84.0M (in $), with an average decrease of 162.5% per quarter

  • Vs WST

    In the last 1 year, West Pharmaceutical Services Inc has given 44.0% return, outperforming this stock by 44.2%

Performance

  • $15.06
    $15.86
    $15.82
    downward going graph

    4.8%

    Downside

    Day's Volatility :5.04%

    Upside

    0.25%

    downward going graph
  • $14.37
    $21.95
    $15.82
    downward going graph

    9.17%

    Downside

    52 Weeks Volatility :34.53%

    Upside

    27.93%

    downward going graph

Returns

PeriodBausch + Lomb Corp.Sector (Health Care)Index (Russel 2000)
3 Months
-13.54%
-1.3%
0.0%
6 Months
-16.12%
1.2%
0.0%
1 Year
1.58%
-5.7%
-6.5%
3 Years
-22.75%
17.1%
-6.5%

Highlights

Market Capitalization
5.4B
Book Value
$19.43
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.59
PEG Ratio
2.57
Wall Street Target Price
29.37
Profit Margin
-5.22%
Operating Margin TTM
6.75%
Return On Assets TTM
1.04%
Return On Equity TTM
-2.88%
Revenue TTM
4.0B
Revenue Per Share TTM
11.33
Quarterly Revenue Growth YOY
6.9%
Gross Profit TTM
2.2B
EBITDA
556.0M
Diluted Eps TTM
-0.59
Quarterly Earnings Growth YOY
-0.89
EPS Estimate Current Year
0.92
EPS Estimate Next Year
0.92
EPS Estimate Current Quarter
0.26
EPS Estimate Next Quarter
0.34

Analyst Recommendation

Buy
    66%Buy
    33%Hold
    0
    0%Sell
Based on 18 Wall street analysts offering stock ratings for Bausch + Lomb Corp.(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
11
11
Hold
6
6
6
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 85.65%

Current $15.82
Target $29.37

Company Financials

FY18Y/Y Change
Revenue
3.7B
-
Net Income
710.0M
-
Net Profit Margin
19.37%
-
FY19Y/Y Change
Revenue
3.8B
↑ 3.08%
Net Income
298.0M
↓ 58.03%
Net Profit Margin
7.89%
↓ 11.48%
FY20Y/Y Change
Revenue
3.4B
↓ 9.69%
Net Income
-17.0M
↓ 105.7%
Net Profit Margin
-0.5%
↓ 8.39%
FY21Y/Y Change
Revenue
3.8B
↑ 10.35%
Net Income
182.0M
↓ 1170.59%
Net Profit Margin
4.83%
↑ 5.33%
FY22Y/Y Change
Revenue
3.8B
↑ 0.08%
Net Income
15.0M
↓ 91.76%
Net Profit Margin
0.4%
↓ 4.43%
Q2 FY22Q/Q Change
Revenue
941.0M
↑ 5.85%
Net Income
7.0M
↓ 65.0%
Net Profit Margin
0.74%
↓ 1.51%
Q3 FY22Q/Q Change
Revenue
942.0M
↑ 0.11%
Net Income
-15.0M
↓ 314.29%
Net Profit Margin
-1.59%
↓ 2.33%
Q4 FY22Q/Q Change
Revenue
996.0M
↑ 5.73%
Net Income
-1000.0K
↓ 93.33%
Net Profit Margin
-0.1%
↑ 1.49%
Q1 FY23Q/Q Change
Revenue
931.0M
↓ 6.53%
Net Income
-88.0M
↑ 8700.0%
Net Profit Margin
-9.45%
↓ 9.35%
Q2 FY23Q/Q Change
Revenue
1.0B
↑ 11.17%
Net Income
-32.0M
↓ 63.64%
Net Profit Margin
-3.09%
↑ 6.36%
Q3 FY23Q/Q Change
Revenue
1.0B
↓ 2.71%
Net Income
-84.0M
↑ 162.5%
Net Profit Margin
-8.34%
↓ 5.25%
FY19Y/Y Change
Total Assets
11.5B
-
Total Liabilities
1.4B
-
FY20Y/Y Change
Total Assets
11.3B
↓ 1.76%
Total Liabilities
1.3B
↓ 11.0%
FY21Y/Y Change
Total Assets
10.8B
↓ 3.93%
Total Liabilities
1.4B
↑ 11.19%
FY22Y/Y Change
Total Assets
11.1B
↑ 2.97%
Total Liabilities
4.0B
↑ 184.52%
Q2 FY22Q/Q Change
Total Assets
11.0B
↑ 0.87%
Total Liabilities
4.0B
↑ 9.21%
Q3 FY22Q/Q Change
Total Assets
10.7B
↓ 2.78%
Total Liabilities
3.9B
↓ 3.23%
Q4 FY22Q/Q Change
Total Assets
11.1B
↑ 4.19%
Total Liabilities
4.0B
↑ 3.64%
Q1 FY23Q/Q Change
Total Assets
11.2B
↑ 0.22%
Total Liabilities
4.1B
↑ 1.83%
Q2 FY23Q/Q Change
Total Assets
11.3B
↑ 1.31%
Total Liabilities
4.3B
↑ 4.08%
Q3 FY23Q/Q Change
Total Assets
13.1B
↑ 15.49%
Total Liabilities
6.2B
↑ 44.34%
FY18Y/Y Change
Operating Cash Flow
763.0M
-
Investing Cash Flow
-74.0M
-
Financing Cash Flow
-665.0M
-
FY19Y/Y Change
Operating Cash Flow
799.0M
↑ 4.72%
Investing Cash Flow
-186.0M
↑ 151.35%
Financing Cash Flow
-606.0M
↓ 8.87%
FY20Y/Y Change
Operating Cash Flow
522.0M
↓ 34.67%
Investing Cash Flow
-256.0M
↑ 37.63%
Financing Cash Flow
-232.0M
↓ 61.72%
FY21Y/Y Change
Operating Cash Flow
873.0M
↑ 67.24%
Investing Cash Flow
-214.0M
↓ 16.41%
Financing Cash Flow
-712.0M
↑ 206.9%
FY22Y/Y Change
Operating Cash Flow
345.0M
↓ 60.48%
Investing Cash Flow
-215.0M
↑ 0.47%
Financing Cash Flow
81.0M
↓ 111.38%
Q1 FY22Q/Q Change
Operating Cash Flow
3.0M
↓ 98.15%
Investing Cash Flow
-41.0M
↓ 49.38%
Financing Cash Flow
52.0M
↓ 240.54%
Q2 FY22Q/Q Change
Operating Cash Flow
156.0M
↑ 5100.0%
Investing Cash Flow
-35.0M
↓ 14.63%
Financing Cash Flow
145.0M
↑ 178.85%
Q3 FY22Q/Q Change
Operating Cash Flow
27.0M
↓ 82.69%
Investing Cash Flow
-49.0M
↑ 40.0%
Financing Cash Flow
-109.0M
↓ 175.17%
Q4 FY22Q/Q Change
Operating Cash Flow
159.0M
↑ 488.89%
Investing Cash Flow
-90.0M
↑ 83.67%
Financing Cash Flow
-7.0M
↓ 93.58%
Q1 FY23Q/Q Change
Operating Cash Flow
-56.0M
↓ 135.22%
Investing Cash Flow
-64.0M
↓ 28.89%
Financing Cash Flow
91.0M
↓ 1400.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-24.0M
↓ 57.14%
Investing Cash Flow
-28.0M
↓ 56.25%
Financing Cash Flow
90.0M
↓ 1.1%

Technicals Summary

Sell

Neutral

Buy

Bausch + Lomb Corp. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bausch + Lomb Corp.
Bausch + Lomb Corp.
-6.98%
-16.12%
1.58%
-22.75%
-22.75%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
13.68%
-0.72%
16.86%
21.18%
82.26%
Resmed Inc.
Resmed Inc.
3.74%
-28.13%
-27.22%
-23.87%
42.37%
Becton, Dickinson And Company
Becton, Dickinson And Company
-8.05%
-6.2%
-3.23%
-1.86%
-2.72%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
5.63%
2.44%
46.92%
29.55%
222.0%
Alcon Ag
Alcon Ag
2.56%
-4.35%
11.05%
19.39%
30.69%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bausch + Lomb Corp.
Bausch + Lomb Corp.
914.0
NA
2.57
0.92
-0.03
0.01
0.0
19.43
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
74.65
74.65
3.27
5.59
0.13
0.08
0.0
35.62
Resmed Inc.
Resmed Inc.
24.98
24.98
1.74
6.52
0.24
0.12
0.01
28.9
Becton, Dickinson And Company
Becton, Dickinson And Company
46.93
46.93
2.31
12.22
0.06
0.03
0.02
88.83
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
47.61
47.61
4.06
7.99
0.21
0.13
0.0
38.76
Alcon Ag
Alcon Ag
80.48
80.48
NA
2.72
0.02
0.02
0.0
40.86
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bausch + Lomb Corp.
Bausch + Lomb Corp.
Buy
$5.4B
-22.75%
914.0
-5.22%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$112.0B
82.26%
74.65
22.14%
Resmed Inc.
Resmed Inc.
Buy
$22.6B
42.37%
24.98
20.72%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$69.3B
-2.72%
46.93
7.66%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$26.1B
222.0%
47.61
19.12%
Alcon Ag
Alcon Ag
Buy
$36.0B
30.69%
80.48
4.85%

Institutional Holdings

  • Fidelity International Ltd

    1.87%

  • Goldentree Asset Management LP

    1.65%

  • Eminence Capital LLC

    1.53%

  • BlackRock Inc

    1.11%

  • ICAHN CARL C

    1.00%

  • Maple Rock Capital Partners, Inc.

    0.82%

Company Information

bausch and lomb corp is a renewables and environment company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.

Organization
Bausch + Lomb Corp.
Employees
13000
CEO
Mr. Joseph C. Papa
Industry
Healthcare

Discover More

FAQs